What is gastroparesis?
Gastroparesis is a medical condition in which the stomach takes much longer than normal to empty its contents into the small intestine. Symptoms include severe nausea, vomiting (often of undigested food eaten hours or days earlier), abdominal pain, bloating, early fullness, and unexplained weight loss.
The condition can be debilitating. Many patients are repeatedly hospitalized, require feeding tubes, lose the ability to work, and live with chronic pain and malnutrition. There is no cure.
How GLP-1 drugs cause gastroparesis
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) intentionally slow stomach emptying — that's part of how they help with weight loss and blood-sugar control.
In some patients, this slowing becomes permanent. Lawsuits allege Novo Nordisk and Eli Lilly knew or should have known that long-term use could cause clinically significant gastroparesis but failed to adequately warn patients and doctors.
Do I qualify for an Ozempic gastroparesis claim?
You may qualify if you (1) took a GLP-1 drug for at least several months, (2) were medically diagnosed with gastroparesis or delayed gastric emptying — typically confirmed by a gastric emptying study — and (3) had no diagnosis of gastroparesis before starting the drug.
A free case review will determine whether your specific facts fit the current MDL criteria.
Compensation in gastroparesis cases
Gastroparesis claims may seek recovery for past and future medical care, lost income, diminished earning capacity, pain and suffering, and in some cases punitive damages. Cases involving repeated hospitalizations, feeding tubes, or permanent disability are valued at the higher end of the range.